Article thumbnail

Triple Negative Breast Cancer – An Overview

By Kartik Aysola, Akshata Desai, Crystal Welch, Jingyao Xu, Yunlong Qin, Charlotte Owens, Joel Okoli, Derrick J Beech, Rika J, Shyam P Reddy and Veena N Rao

Abstract

Triple Negative Breast Cancer (TNBC) is a heterogeneous disease that based on immunohistochemistry (IHC) is estrogen receptor (ER) negative, progesterone receptor (PR) negative and human epidermal growth factor receptor 2 (HER2) negative. TNBC is typically observed in young AA women and Hispanic women who carry a mutation in the BRCA1 gene. TNBC is characterized by a distinct molecular profile, aggressive nature and lack of targeted therapies. The purpose of this article is to review the current and future novel signalling pathways as therapeutic approaches to TNBC. Recent Identification of a new BRCA1 trafficking pathway holds promise in the future for the development of targeted therapies for TNBC

Year: 2016
OAI identifier: oai:CiteSeerX.psu:10.1.1.853.7150
Provided by: CiteSeerX
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://europepmc.org/backend/p... (external link)
  • http://europepmc.org/backend/p... (external link)
  • http://citeseerx.ist.psu.edu/v... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.